Lung cancer: Stopping immunotherapy after 2 years may not affect mortality risk
For people with late-stage non-small cell lung cancer (NSCLC) undergoing initial immunotherapy treatment, a key question has been how long they should continue the therapy for the best chance at survival.
A recent retrospective study examined medical records to compare the outcomes of people who stopped immunotherapy around the two-year mark with those who continued beyond that point.
The findings suggest that stopping treatment after two years doesn’t seem to negatively affect survival rates, potentially offering reassurance to patients and healthcare providers contemplating whether to discontinue the treatment at that stage.
In their study, recently published in JAMA OncologyTrusted Source, the researchers looked at medical records of adults diagnosed with late-stage NSCLC between 2016 and 2020 and started their treatment with immunotherapy.
The study focused on two different treatment paths: one where treatment was stopped at around two years (specifically between 700 and 760 days), and another where treatment continued for more than two years (more than 760 days).
Dr. Haiying Cheng, an associate professor of oncology and medicine at the Albert Einstein College of Medicine as well as an oncologist at Montefiore Health System said that “immunotherapy has emerged as a significant breakthrough in the treatment of advanced NSCLC.”
“Yet, one question remains elusive: what is the ideal duration for immunotherapy? A two-year duration of immunotherapy has been commonly considered; however, a substantial number of patients opt to extend their treatment beyond this timeframe,” Dr. Cheng, who was not involved the study, told MNT.
https://www.ajmc.com/view/novel-pet-based-radiomics-signature-predicts-car-t-efficacy-in-dlbcl
ارسال به دوستان